US Authorisation of Non-Voluntary Use of Patents frequently used for health technologies
During the Covid-19 pandemic, the United States prioritised the rapid development of products needed to combat the health crisis. Rapid product development was pursued...
The European Commission’s proposal on a new EU-wide compulsory licensing regime
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London
A recent international health emergency, the...
The new IP strategy of war-torn Ukraine should prioritise public health and national security
Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...
Synthesis and Conclusions: Securing technology transfer in the Pandemic Agreement
This guest blog draws from the discussions at a 27 January 2025 expert workshop organised by the Geneva Graduate Institute entitled Technology Transfer in...
WHO Fair Pricing Forum: Watching for Drug Industry Accountability
by Katrina Perehudoff and Jennifer Sellin
Expensive medicines are a ubiquitous challenge from which no government is immune. Excessive price hikes are an urgent human...
Commission report on competition enforcement in the pharmaceutical sector
Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...
The People vs. AbbVie
Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...
Some Surprises in the European Commission’s New Intellectual Property Strategy
The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
Strong call for transparency on medicine prices, cost of R&D at WHO Fair Pricing...
“Medical innovation has little social value if most people cannot access its benefits…. this is a global human rights issue,” said Mariângela Simão, Assistant...